Literature DB >> 26660150

Beyond current aprepitant evidence: room for improvement on dose selection and chemotherapy-induced nausea and vomiting risk factors.

Lucas Miyake Okumura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26660150     DOI： 10.1007/s00520-015-3046-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  8 in total

1.  Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.

Authors:  Megan Bodge; Alexandra Shillingburg; Stephan Paul; Lisa Biondo
Journal:  Pediatr Blood Cancer       Date:  2013-12-19       Impact factor: 3.167

2.  Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.

Authors:  Sameer Bakhshi; Atul Batra; Bivas Biswas; Deepa Dhawan; Reeja Paul; Vishnubhatla Sreenivas
Journal:  Support Care Cancer       Date:  2015-04-08       Impact factor: 3.603

3.  Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents.

Authors:  Angela R Smith; Tanya L Repka; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2005-11       Impact factor: 3.167

4.  Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.

Authors:  Alexander Molassiotis; Matti Aapro; Mario Dicato; Pere Gascon; Sylvia A Novoa; Nicolas Isambert; Thomas A Burke; Anna Gu; Fausto Roila
Journal:  J Pain Symptom Manage       Date:  2013-09-24       Impact factor: 3.612

5.  Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.

Authors:  Hyoung Jin Kang; Susan Loftus; Arlene Taylor; Cara DiCristina; Stuart Green; Christian Michel Zwaan
Journal:  Lancet Oncol       Date:  2015-03-12       Impact factor: 41.316

6.  Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.

Authors:  Lia Gore; Sant Chawla; Antonio Petrilli; Molly Hemenway; Debra Schissel; Vickey Chua; Alexandra D Carides; Arlene Taylor; Suzanne Devandry; Jack Valentine; Judith K Evans; Bettina Oxenius
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

7.  How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study.

Authors:  Julie Vanbockstael; Elodie Coquan; Sophie Gouerant; Djelila Allouache; Audrey Faveyrial; Sabine Noal; Corinne Delcambre; Marie-Pierre Galais; Jean-François Héron; Anne-Charlotte Lefebvre; Emmanuel Sevin; Ioana Hrab; Florence Polycarpe; Michel André; Laure Kaluzinski; Radj Gervais; Katharina Gunzer; Brigitte Vié; Gilles Saucier; Noëmie Lemenand; Jean-Michel Grellard; Bénédicte Clarisse; Audrey Emmanuelle Dugué; Florence Joly
Journal:  Support Care Cancer       Date:  2015-08-14       Impact factor: 3.603

8.  Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients.

Authors:  L Lee Dupuis; Sabrina Boodhan; Mark Holdsworth; Paula D Robinson; Richard Hain; Carol Portwine; Erin O'Shaughnessy; Lillian Sung
Journal:  Pediatr Blood Cancer       Date:  2013-03-19       Impact factor: 3.167
  8 in total
  1 in total

1.  Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials.

Authors:  Lucas Miyake Okumura; Fernanda D'Athayde Rodrigues; Maria Angelica Pires Ferreira; Leila Beltrami Moreira
Journal:  Br J Clin Pharmacol       Date:  2017-01-12       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.